Source 1primary paper2025MED
Toolkit/GVs-HV@MM-Lipo
GVs-HV@MM-Lipo
Also known as: macrophage membrane/lipid membrane fusion bio-vesicles
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
GVs-HV@MM-Lipo exerts potent anti-atherosclerotic and anti-inflammatory effects with favorable safety.
Usefulness & Problems
No literature-backed usefulness or problem-fit explainer has been materialized for this record yet.
Published Workflows
Objective: Engineer and evaluate a macrophage-membrane-fused liposomal gene-delivery system carrying a Hirudin-Gas Vesicle recombinant plasmid for targeted anti-atherosclerosis therapy, including ultrasound-assisted plaque treatment.
Why it works: The abstract presents a complementary mechanism in which macrophage-membrane proteins support lesion targeting, the plasmid achieves intracellular delivery and transfection, and the encoded hirudin and gas vesicle functions jointly support plaque disruption and anti-inflammatory therapy.
integrin α4β21-mediated inflammatory vascular targetinglysosomal escape and nuclear entry of delivered plasmidultrasound-triggered gas vesicle cavitation for plaque disruptionhirudin-mediated fragment ablation, anti-inflammatory activity, and lipid regulationrecombinant plasmid constructionmacrophage membrane/lipid membrane fusion vesicle deliveryultrasound-assisted therapy
Stages
- 1.Recombinant plasmid construction(library_build)
To create the therapeutic genetic payload used in the delivery system.
Selection: Construction of a Hirudin-Gas Vesicle recombinant plasmid for gene delivery.
- 2.Biomimetic delivery system assembly and targeting feature retention(functional_characterization)
To provide lesion-targeting delivery of the recombinant plasmid.
Selection: Use macrophage membrane/lipid membrane fusion bio-vesicles retaining integrin α4β21 for inflammatory vascular delivery.
- 3.Intracellular trafficking and transfection characterization(secondary_characterization)
To verify that the delivered plasmid can reach the nucleus and function after targeted delivery.
Selection: Assess lysosomal escape, nuclear entry, and highly efficient transfection.
- 4.Ultrasound-assisted mechanistic testing(confirmatory_validation)
To confirm the mechanistic contribution of gas vesicles under ultrasound.
Selection: Test whether gas vesicles can break up lesion plaques with in vitro ultrasound.
- 5.Mouse therapeutic evaluation(in_vivo_validation)
To test whether the engineered system produces therapeutic benefit in an animal atherosclerosis context.
Selection: Evaluate plaque regression, anti-inflammatory effects, safety, and hemodynamic improvement in mice.
Steps
- 1.Construct Hirudin-Gas Vesicle recombinant plasmidengineered therapeutic genetic payload
Create the combined hirudin and gas vesicle plasmid used for gene delivery.
The therapeutic payload must be built before it can be loaded into the delivery vesicles.
- 2.Deliver plasmid using macrophage membrane/lipid membrane fusion bio-vesiclespayload and delivery harness
Enable targeted delivery of the recombinant plasmid to inflammatory vascular lesions.
Targeted delivery is needed before intracellular trafficking and therapeutic action can be evaluated.
- 3.Assess lysosomal escape, nuclear entry, and transfectiondelivered plasmid under test
Verify that the delivered plasmid reaches the nucleus and supports efficient transfection.
Intracellular trafficking must be confirmed after delivery and before attributing downstream therapeutic effects to the construct.
- 4.Apply in vitro ultrasound to test gas-vesicle-mediated plaque breakupultrasound-responsive therapeutic component
Confirm that gas vesicles contribute plaque-disruption activity under ultrasound.
This mechanistic test links the gas-vesicle component to the intended ultrasound-assisted therapeutic effect before or alongside in vivo efficacy interpretation.
- 5.Compare liposomal and macrophage-membrane-fused formulations in mice, including ultrasound-assisted treatmenttherapeutic formulations under comparison
Evaluate in vivo plaque regression, anti-inflammatory effects, safety, and hemodynamic outcomes.
Animal testing is used as the higher-fidelity validation stage after mechanistic and delivery rationale are established.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Mechanisms
biomimetic vascular targeting via integrin α4β21-mediated binding to vascular adhesion moleculeslysosomal escapenuclear entry for transfectionultrasound-responsive plaque disruption mediated by gas vesiclesTechniques
No technique tags yet.
Target processes
No target processes tagged yet.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
The Hirudin-Gas Vesicle recombinant plasmid could escape lysosomes and enter the nucleus to achieve highly efficient transfection.
GVs-HV@Lipo reduced mice aortic arch plaque area by 17%, and GVs-HV@MM-Lipo plus ultrasound achieved further plaque regression and improved hemodynamics.
aortic arch plaque area reduction 17 %
The study constructed a Hirudin-Gas Vesicle recombinant plasmid for gene delivery using macrophage membrane/lipid membrane fusion bio-vesicles.
Gas vesicles can break up lesion plaques with in vitro ultrasound, while hirudin mediates fragment ablation and anti-inflammatory and lipid-regulatory effects.
The bio-fusion vesicles retained macrophage membrane protein integrin α4β21 to bind vascular adhesion molecules highly expressed by inflammatory cells and achieve delivery.
GVs-HV@MM-Lipo exerts potent anti-atherosclerotic and anti-inflammatory effects with favorable safety.
Approval Evidence
1 source4 linked approval claimsfirst-pass slug gvs-hv-mm-lipo
GVs-HV@MM-Lipo exerts potent anti-atherosclerotic and anti-inflammatory effects with favorable safety.
Source:
comparative performancesupports
GVs-HV@Lipo reduced mice aortic arch plaque area by 17%, and GVs-HV@MM-Lipo plus ultrasound achieved further plaque regression and improved hemodynamics.
Source:
constructionsupports
The study constructed a Hirudin-Gas Vesicle recombinant plasmid for gene delivery using macrophage membrane/lipid membrane fusion bio-vesicles.
Source:
targeting mechanismsupports
The bio-fusion vesicles retained macrophage membrane protein integrin α4β21 to bind vascular adhesion molecules highly expressed by inflammatory cells and achieve delivery.
Source:
therapeutic effectsupports
GVs-HV@MM-Lipo exerts potent anti-atherosclerotic and anti-inflammatory effects with favorable safety.
Source:
Comparisons
No literature-backed comparison notes have been materialized for this record yet.
Ranked Citations
- 1.